Stocks· September 11, 2026 at 01:14 PM
Authored by·Editorially reviewed
Onur Erkan YıldızFounder, Financial Engineer · CMB-licensed
Higher education in Financial Engineering and Money & Capital Markets. SPK (Turkey CMB) licence. 16 years across institutional markets, research, and quant-driven analytics.
NeutralMedium impact
AI summary
Investing.com -- JPMorgan revealed Friday that it has started coverage of Hims & Hers Health at Neutral, setting a December 2027 price target of $32 as it weighs the direct-to-consumer health platform's rapid growth against execution risks in its shift to branded weight-loss drugs.
Affected symbols
AI commentary is generated from public news feeds and is not investment advice.
Related coverage
StocksMedium impactNeutral39m
Can Greece Add Another Growth Lever for JPMorgan in Europe?
via Yahoo Finance
JPM
StocksMedium impactNeutral43m
Forget the Capex Fears: Why Alphabet and Amazon Are Must-Buys
via Yahoo Finance
AMZN
StocksMedium impactNeutral45m
Equity risk premium falls to 2002 levels. What it means for stocks
via Yahoo Finance
JPM
StocksMedium impactNeutral53m
Fidji Simo joins Nscale board ahead of IPO
via Yahoo Finance
META